Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 953 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Otsuka, H Lundbeck to develop neuroscience products

The collaboration covers two late stage compounds from Otsuka- aripiprazole depot formulation and OPC-34712. Aripiprazole depot formulation for schizophrenia is a sterile, lyophilized cake that when reconstituted with

FDA approves Watson ANDA for Kadian

Kadian is used for management of moderate to severe pain that lasts for an extended period of time. Following the approval, the company has started shipping the product.

Santen Sirolimus drug secures FDA orphan drug status

Sirolimus, an immunosuppressive and anti-proliferative agent, is being assessed in double-masKed Uveitis tReAtment (SAKURA) Phase III study to demonstrate the safety and efficacy of different doses of sirolimus

Boehringer funds NCCN Oncology Research Program

Afatinib is an oral, once-daily, tyrosine kinase inhibitor which is being investigated for various tumor types including non-small cell lung (NSCL), breast, head and neck, and colorectal cancers

Wolters to sell pharma-related business to Springer

The Marketing & Publishing Services business unit is part of the Wolters’ Health & Pharma Solutions division. Marketing & Publishing Services provides business intelligence, strategic marketing and publishing

Daiichi Sankyo, ArQule in license agreement

Both the companies have jointly developed ARQ 092 by utlizing ArQule Kinase Inhibitor Platform (AKIP) technology, as per the agreement signed in November 2008. Daiichi Sankyo will retain